Unfortunately, there is no clear answer. Dr. Wigley in the Johns Hopkins Scleroderma Center is part of a multicenter study looking at cyclophosphamide in scleroderma interstitial lung disease. Some earlier studies have suggested that cyclophosphamide is useful when there is active inflammation in the lung diagnosed with high resolution CT scan showing alveolitis, bronchoalveolar lavage, or rapidly declining PFTs. But other agents such as azathioprine (Imuran) have also been used. There is no clear answer as of yet.
Your Gift of $75 Will Provide A Full Day of Access to this Site
More than 15 years ago the Arthritis Center launched this website with the mission to bring current and accurate disease education to health care professionals and patients alike. Today, over 1 Million people visit this site each year. Content on our site is generated directly by our team members. Unlike many health education websites we do not accept advertising, paid guests posts or charge for access to our site.
That’s where you come in. Your gift of just $75 will deliver this valuable information to patients and healthcare professionals for a full day.Give TodayMore Ways to Make an Impact